Burcon Nutrascience Reports Strong Revenue Growth as Stonegate Capital Updates Coverage

Stonegate Capital Partners has updated its coverage on Burcon Nutrascience Corporation (TSX: BU), highlighting the company's transition from technology validation to commercial execution. The report, released on August 13, 2026, details Burcon's first-quarter fiscal 2027 results, which show a marked increase in revenue and customer traction.

Revenue for the quarter reached $1.28 million, a 54% increase quarter-over-quarter and a 273% increase year-over-year. The number of active buying customers grew to 40, up from over 30 previously, and repeat purchasing continues to build, indicating growing demand for Burcon's plant-based protein products. This momentum is a positive sign for the company as it works to establish a foothold in the competitive alternative protein market.

However, the quarter was not without challenges. Burcon recorded a $1.76 million inventory write-down, which masked a much narrower underlying gross loss. Excluding this non-cash charge, the company's operational performance improved significantly, reflecting better cost management and production efficiencies. The focus now shifts to whether the improving customer traction can support the sizable revenue ramp required in the second half of the fiscal year to reach the prior CY26 sales objective of $10 million.

To achieve this target, Burcon will need to generate approximately $7.9 million in sales during the second half, a substantial increase from current levels. The company is taking steps to position itself for this growth, including expanding its Galesburg production capacity and securing additional funding. A planned financing of up to $8.1 million is intended to bridge liquidity and support the production ramp, which is critical for meeting customer demand and moving toward positive cash flow.

The implications of Burcon's progress extend beyond the company itself. As a player in the plant-based protein sector, Burcon's ability to scale production and achieve commercial success could contribute to the broader adoption of sustainable protein sources. For Texas, where the company's operations and partnerships may have economic ripple effects, the expansion in Galesburg and increased sales activity could create jobs and strengthen the local supply chain.

Stonegate Capital Partners, a leading capital markets advisory firm, provides investor relations and equity research services for public companies. Its coverage update offers valuable insights for investors monitoring Burcon's execution against its strategic goals. The full announcement, including additional details and visuals, is available through Stonegate's distribution channels.

As Burcon navigates this critical phase, the market will be watching closely to see if the company can translate its growing customer base into sustained revenue growth and eventually achieve profitability. The next quarters will be pivotal in determining whether Burcon can meet its ambitious targets and solidify its position in the evolving food technology landscape.